FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056893352> ?p ?o ?g. }

• W2056893352 endingPage "1675" @default.
• W2056893352 startingPage "1667" @default.
• W2056893352 abstract "Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure.A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily. The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours.Overall mortality was similar in the two groups. The incidence of the combined end point, however, was 13.2 percent lower with valsartan than with placebo (relative risk, 0.87; 97.5 percent confidence interval, 0.77 to 0.97; P=0.009), predominantly because of a lower number of patients hospitalized for heart failure; 455 (18.2 percent) in the placebo group and 346 (13.8 percent) in the valsartan group (P<0.001). Treatment with valsartan also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure, and quality of life as compared with placebo (P<0.01). In a post hoc analysis of the combined end point and mortality in subgroups defined according to base-line treatment with angiotensin-converting-enzyme (ACE) inhibitors or beta-blockers, valsartan had a favorable effect in patients receiving neither or one of these types of drugs but an adverse effect in patients receiving both types of drugs.Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination." @default.
• W2056893352 created "2016-06-24" @default.
• W2056893352 creator A5005350140 @default.
• W2056893352 creator A5018464718 @default.
• W2056893352 date "2001-12-06" @default.
• W2056893352 modified "2023-10-18" @default.
• W2056893352 title "A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure" @default.
• W2056893352 cites W1889292854 @default.
• W2056893352 cites W1973222295 @default.
• W2056893352 cites W1975603373 @default.
• W2056893352 cites W2010740097 @default.
• W2056893352 cites W2013658571 @default.
• W2056893352 cites W2022631518 @default.
• W2056893352 cites W2022904157 @default.
• W2056893352 cites W2036513040 @default.
• W2056893352 cites W2037407509 @default.
• W2056893352 cites W2046383587 @default.
• W2056893352 cites W2052780003 @default.
• W2056893352 cites W2058399305 @default.
• W2056893352 cites W2071172710 @default.
• W2056893352 cites W2074356541 @default.
• W2056893352 cites W2100082183 @default.
• W2056893352 cites W2115526864 @default.
• W2056893352 cites W2118626367 @default.
• W2056893352 cites W2135757164 @default.
• W2056893352 cites W2140692337 @default.
• W2056893352 cites W2296998040 @default.
• W2056893352 cites W2323458614 @default.
• W2056893352 cites W2326508838 @default.
• W2056893352 cites W2585382523 @default.
• W2056893352 cites W4245244523 @default.
• W2056893352 cites W4246381244 @default.
• W2056893352 cites W52877415 @default.
• W2056893352 doi "https://doi.org/10.1056/nejmoa010713" @default.
• W2056893352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11759645" @default.
• W2056893352 hasPublicationYear "2001" @default.
• W2056893352 type Work @default.
• W2056893352 sameAs 2056893352 @default.
• W2056893352 citedByCount "2867" @default.
• W2056893352 countsByYear W20568933522012 @default.
• W2056893352 countsByYear W20568933522013 @default.
• W2056893352 countsByYear W20568933522014 @default.
• W2056893352 countsByYear W20568933522015 @default.
• W2056893352 countsByYear W20568933522016 @default.
• W2056893352 countsByYear W20568933522017 @default.
• W2056893352 countsByYear W20568933522018 @default.
• W2056893352 countsByYear W20568933522019 @default.
• W2056893352 countsByYear W20568933522020 @default.
• W2056893352 countsByYear W20568933522021 @default.
• W2056893352 countsByYear W20568933522022 @default.
• W2056893352 countsByYear W20568933522023 @default.
• W2056893352 crossrefType "journal-article" @default.
• W2056893352 hasAuthorship W2056893352A5005350140 @default.
• W2056893352 hasAuthorship W2056893352A5018464718 @default.
• W2056893352 hasBestOaLocation W20568933521 @default.
• W2056893352 hasConcept C104849204 @default.
• W2056893352 hasConcept C126322002 @default.
• W2056893352 hasConcept C142724271 @default.
• W2056893352 hasConcept C164705383 @default.
• W2056893352 hasConcept C168563851 @default.
• W2056893352 hasConcept C203092338 @default.
• W2056893352 hasConcept C204787440 @default.
• W2056893352 hasConcept C27081682 @default.
• W2056893352 hasConcept C2777387769 @default.
• W2056893352 hasConcept C2778198053 @default.
• W2056893352 hasConcept C2908929049 @default.
• W2056893352 hasConcept C71924100 @default.
• W2056893352 hasConcept C78085059 @default.
• W2056893352 hasConcept C84393581 @default.
• W2056893352 hasConceptScore W2056893352C104849204 @default.
• W2056893352 hasConceptScore W2056893352C126322002 @default.
• W2056893352 hasConceptScore W2056893352C142724271 @default.
• W2056893352 hasConceptScore W2056893352C164705383 @default.
• W2056893352 hasConceptScore W2056893352C168563851 @default.
• W2056893352 hasConceptScore W2056893352C203092338 @default.
• W2056893352 hasConceptScore W2056893352C204787440 @default.
• W2056893352 hasConceptScore W2056893352C27081682 @default.
• W2056893352 hasConceptScore W2056893352C2777387769 @default.
• W2056893352 hasConceptScore W2056893352C2778198053 @default.
• W2056893352 hasConceptScore W2056893352C2908929049 @default.
• W2056893352 hasConceptScore W2056893352C71924100 @default.
• W2056893352 hasConceptScore W2056893352C78085059 @default.
• W2056893352 hasConceptScore W2056893352C84393581 @default.
• W2056893352 hasIssue "23" @default.
• W2056893352 hasLocation W20568933521 @default.
• W2056893352 hasLocation W20568933522 @default.
• W2056893352 hasOpenAccess W2056893352 @default.
• W2056893352 hasPrimaryLocation W20568933521 @default.
• W2056893352 hasRelatedWork W2385466232 @default.
• W2056893352 hasRelatedWork W2604998822 @default.
• W2056893352 hasRelatedWork W2805169473 @default.
• W2056893352 hasRelatedWork W2971294569 @default.
• W2056893352 hasRelatedWork W3013207865 @default.
• W2056893352 hasRelatedWork W3033076790 @default.
• W2056893352 hasRelatedWork W3111618423 @default.
• W2056893352 hasRelatedWork W4207018476 @default.
• W2056893352 hasRelatedWork W4315752829 @default.
• W2056893352 hasRelatedWork W4319600715 @default.

• next